Cautious optimism about new drug for Alzheimer’s

Cliff Abraham. Photo: Supplied
Cliff Abraham. Photo: Supplied
Dunedin brain researcher Prof Cliff Abraham is "cautiously hopeful" about the first new Alzheimer’s drug to be approved by the United States Food and Drug Administration in nearly 20 years.

Prof Abraham said the recently approved drug, Biogen Inc’s aducanumab, had taken an "antibody approach", different from existing Alzheimer’s medications.

The new drug also aims to treat the condition itself, by removing sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of Alzheimer’s.

This seeks to slow the disease effects, including memory loss, Reuters has reported.

About 70,000 New Zealanders have dementia and Prof Abraham believes about 10,000 people are in the early stages of the Alzheimer’s.

"Bottom line, I think this is the FDA responding to the need more than actual data," Prof Abraham, of the University of Otago psychology department, said yesterday.

More data, more evidence and a further clinical trial were needed to clarify any benefits from the new drug.

The supporting information already available was "not strong", he said.

"And what was not tested and what we don't know, is whether any small clinical benefit is any better than what the existing drugs provide," Prof Abraham said.

For such reasons, at about $US56,000 a year, he would be "very surprised" if Pharmac approved it for subsidy, although the medicine subsidy-approving agency would be under the same pressures as the FDA.

"Even a glimmer of hope is better than none in people's minds, which will put the pressure on," he said.

Prof Abraham, who is also co-director of Brain Research New Zealand, said caution was needed until a further clinical trial was held.

"The fact that the FDA's own advisory committee recommended not to approve it is telling," he said.

FDA Centre for Drug Evaluation and Research director Dr Patrizia Cavazzoni said Alzheimer’s disease was a "devastating illness"and the new drug was the first "to target and affect" the disease process and not just the symptoms.

john.gibb@odt.co.nz

Add a Comment

Our journalists are your neighbours

We are the South's eyes and ears in crucial council meetings, at court hearings, on the sidelines of sporting events and on the frontline of breaking news.

As our region faces uncharted waters in the wake of a global pandemic, Otago Daily Times continues to bring you local stories that matter.

We employ local journalists and photographers to tell your stories, as other outlets cut local coverage in favour of stories told out of Auckland, Wellington and Christchurch.

You can help us continue to bring you local news you can trust by becoming a supporter.

Become a Supporter